Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2019-10-11 Major Shareholding Noti…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
191011- Transparantieverklaring persbericht BlackRock.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Transparantieverklaring BlackRock, Inc." (Transparency Declaration BlackRock, Inc.) and explicitly mentions the crossing of a major shareholding threshold ("Overschreden drempel: 5%"). It details the acquisition of voting shares by BlackRock, Inc. and its affiliated companies, referencing Belgian law regarding the disclosure of major shareholdings. This content directly corresponds to notifications required when an investor's stake crosses specific thresholds, which falls under the category of Major Shareholding Notification (MRQ). Although it is a formal disclosure, it is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific filing about ownership change.
2019-10-11 Dutch
UCB Ra Pharma Oct 10 2019 ENG
M&A Activity Classification · 99% confidence The document is a press release dated October 10, 2019, announcing that UCB has entered into a merger agreement to acquire Ra Pharmaceuticals. It details the transaction terms (US$ 48 cash per share, total value approx. US$ 2.1 billion), strategic rationale (pipeline enhancement, technology platform acquisition), and financial guidance impact. The text explicitly states it is 'regulated information – inside information' and discusses a corporate transaction (merger/acquisition). This type of announcement, detailing a major corporate action like an acquisition, is typically classified as a significant corporate event announcement. While it impacts financing (CAP) and management structure (MANG), the core event is the M&A activity. The closest specific category is 'M&A Activity' (TAR). It is not a standard periodic report (10-K, IR, ER) nor a simple financing update (CAP), but a specific takeover/merger announcement.
2019-10-10 English
UCB Ra Pharma Oct 10 2019 FR
M&A Activity Classification · 99% confidence The document is a press release dated October 10, 2019, announcing that UCB is acquiring Ra Pharmaceuticals. It details the terms of the transaction (cash offer per share), the strategic rationale (pipeline enhancement, especially for Myasthenia Gravis), financial implications (delay of medium-term targets), and includes boilerplate information about the companies and advisors. The text explicitly states it contains "Informations réglementées" and "Informations privilégiées" (Regulated Information / Inside Information) and concludes with details for an investor conference call. This structure is characteristic of a major corporate transaction announcement, which falls under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a general announcement. However, since the core subject is the acquisition, financing, and capital structure change resulting from the merger, 'Capital/Financing Update' (CAP) is the most specific fit, as it covers fundraising and capital structure changes, which an acquisition financed by debt and equity structure changes implies. It is not a standard 10-K, ER, or IR, but a specific corporate action announcement.
2019-10-10 French
UCB Ra Pharma Oct 10 2019 NL
M&A Activity Classification · 98% confidence The document is a press release dated October 10, 2019, announcing that UCB has entered into a definitive agreement to acquire Ra Pharmaceuticals Inc. The text details the transaction terms (US$ 48 cash per share), the strategic rationale (strengthening the pipeline, especially for myasthenia gravis with zilucoplan), financing details (existing cash and new term loans), and the expected closing timeline (end of Q1 2020). This content describes a significant corporate action related to fundraising, capital structure, and corporate development, specifically a merger/acquisition. Based on the definitions, the most appropriate code is TAR (M&A Activity). It is not an Earnings Release (ER) or an Interim Report (IR) as it focuses on the transaction, not periodic financial results, and it is not a Report Publication Announcement (RPA) because it is the primary announcement of the M&A event itself, not just a notice that a report is available.
2019-10-10 Dutch
191008-Transparency notification press release Blackrock .pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal transparency notification regarding a change in major shareholding (BlackRock, Inc. crossing the 5% threshold in UCB SA/NV). It explicitly references the 'law of 2 May 2007 on the disclosure of large shareholdings' and provides detailed tables of voting rights and financial instruments. This fits the definition of a Major Shareholding Notification (MRQ).
2019-10-08 English
191008- Notification de transparence comm.de presse Blackrock.pdf
Major Shareholding Notification Classification · 100% confidence The document is a 'Déclaration de transparence' (Transparency Declaration) from UCB SA regarding BlackRock, Inc. crossing a 5% shareholding threshold. This is a standard regulatory notification required when a major shareholder's stake changes significantly. It details the number of voting rights and financial instruments held. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2019-10-08 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.